About this trial
The goal of this study is to measure the accuracy of a new measles rapid test when used in clinical health centres in several regions of Senegal. The rapid test will be used to test patients for measles who attend the participating health centres with signs and symptoms suggestive of measles infection. The rapid test can be used with a drop of blood from a finger, or oral fluid sampled with a swab rubbed over the gums. The rapid test will be compared to the standard methods of diagnosis in the laboratory using blood samples and oral or throat samples taken for surveillance purposes.
The main questions the study aims to answer are:
1. What is the accuracy of the rapid test when used with capillary blood (a drop of blood from the finger tip) in health centres by non-laboratory health professionals? 2. What is the accuracy of the rapid test when used with oral fluid by non-laboratory health professionals?
In addition to measuring the accuracy of the test, data will also be collected on whether the test is easy and practical to use and how best to record the results.
Eligibility criteria
Qualifiers
For whom confirmatory diagnostic testing is currently indicated as per the national surveillance protocol
With clinical signs and symptoms consistent with the WHO suspected measles case definition including: History of fever, or observed fever (>37.5C) at presentation and a (non-vesicular) maculopapular rash; or clinically suspected measles
≤ 28 days after the onset of a rash
Who if <18 years of age, have written, informed consent from their legal guardian (and verbally assent if more than 7 years old)
Disqualifiers
Withdrawal of consent or assent as described above, at any time.
Unsuccessful venous blood sampling after a maximum of 3 attempts, or a serum sample is no longer available for any reason.
Clinical signs or symptoms requiring immediate referral/transfer of the patient to another site or centre, and/or for whom participation would involve a delay of urgent clinical interventions or investigations (i.e. potential inclusion of patients requiring immediate clinical management should be deferred until the patient is clinically stable).
Clinical signs or symptoms that may be exacerbated by blood draw or upper respiratory sampling (e.g. stridor or severe respiratory distress)
Trial design
Treatments tested in this trial
- Not listed